Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Endocrinology

Background:

• Hypertension and diabetes mellitus are major risk factors for endothelial dysfunction and cardiovascular disease.
• Oxidative stress plays a critical role in the pathogenesis of endothelial damage in these conditions.
• Current treatments aim to control blood pressure and mitigate endothelial damage.

Purpose of the Study:

• To compare the efficacy of a fixed-dose combination of olmesartan/amlodipine versus monotherapy with olmesartan or amlodipine.
• To evaluate the impact of these treatments on specific markers of endothelial damage and oxidative stress.
• To assess changes in lipoprotein (a), myeloperoxidase (MPO), isoprostanes, and paraoxonase-1 (PON-1) levels.

Main Methods:

• A randomized trial involving 221 diabetic, hypertensive patients.
• Patients were assigned to olmesartan 20 mg, amlodipine 10 mg, or a fixed olmesartan/amlodipine 20/5 mg combination for 12 months.
• Blood pressure was monitored monthly, and endothelial damage markers were assessed at baseline, 6, and 12 months.

Main Results:

• The fixed olmesartan/amlodipine combination achieved significantly lower blood pressure than monotherapies.
• This combination led to reductions in lipoprotein (a) and isoprostanes levels compared to baseline and monotherapy.
• Paraoxonase-1 (PON-1) levels increased, and myeloperoxidase (MPO) reduction was greater with the fixed combination.

Conclusions:

• The fixed olmesartan/amlodipine combination is more effective than monotherapy in improving endothelial function markers in diabetic, hypertensive patients.
• This combination demonstrates superior efficacy in reducing oxidative stress, specifically by increasing PON-1 and decreasing isoprostanes.
• These findings suggest a beneficial role for fixed-dose combination therapy in managing cardiovascular risk in this patient population.